Ilaris 150 MG/ML vialml
Ended Awarded Last action
- Contract number
- SPE2DR26FQWE9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $26,183
Award facts
- Contract value 100% obligated
- $26,182.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $26,182.60 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 150 mg/ml ILARIS vials. The award, issued on December 3, 2025, with an ultimate completion date of December 24, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and extends through December 31, 2036.
The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supplying pharmaceutical products and medical consumables to support Department of Defense healthcare operations globally. DMS Pharmaceutical Group's contract includes a 30-month base period with three 30-month option periods and authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. ILARIS (canakinumab) is a biologic immunosuppressant used in treating inflammatory conditions, consistent with the company's established portfolio of specialty pharmaceuticals and biologic agents supplied to military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FQWE9?
SPE2DR26FQWE9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FQWE9 worth?
The government has obligated $26,183 on SPE2DR26FQWE9.
Is contract SPE2DR26FQWE9 an order under another contract?
Yes. SPE2DR26FQWE9 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWE9 competed?
The extent of competition for SPE2DR26FQWE9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award